Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

341. Insulin delivery and glucose monitoring methods: future research needs

Insulin delivery and glucose monitoring methods: future research needs Insulin delivery and glucose monitoring methods: future research needs Insulin delivery and glucose monitoring methods: future research needs Yeh H-C, Lau BD, Golden SH, Donner T, Brown TT, Bass EB Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Yeh H-C, Lau BD, Golden (...) SH, Donner T, Brown TT, Bass EB. Insulin delivery and glucose monitoring methods: future research needs. Rockville: Agency for Healthcare Research and Quality (AHRQ). Future Research Needs Paper No.32. 2013 Authors' conclusions For type 1 diabetes, three expert stakeholders ranked adolescents as the highest priority age group for future research, and three stakeholders ranked the artificial pancreas as the highest priority for future research. For future research on glucose monitoring methods

2013 Health Technology Assessment (HTA) Database.

342. Do patients with type 2 diabetes who aren't taking insulin benefit from self-monitoring blood glucose?

Do patients with type 2 diabetes who aren't taking insulin benefit from self-monitoring blood glucose? Do patients with type 2 diabetes who aren't taking insulin benefit from self-monitoring blood glucose? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do patients with type 2 diabetes who aren't taking insulin benefit (...) from self-monitoring blood glucose? View/ Open Date 2013-01 Format Metadata Abstract Patients with type 2 diabetes who aren't on insulin and perform self-monitoring of blood glucose (SMBG) show small but significant reductions in hemoglobin A1c (HbA1c) at 6 months but not at 12 months (strength of recommendation [SOR]: B, systematic reviews and meta-analyses of disease-oriented evidence). Patients with a baseline HbA1c <8% who self-monitor don't reduce their HbA1c levels, but patients

2013 Clinical Inquiries

343. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus (Abstract)

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to insulin in type 2 diabetes mellitus (T2DM).This is a multicentre, double-blind, placebo-controlled, parallel group, clinical trial in T2DM patients inadequately controlled by stable insulin therapy, with or without metformin. Patients received treatment (...) of hypoglycaemia compared with placebo (8.4 vs. 7.2%, p = 0.66) in spite of improved glycaemic control, and was not associated with weight gain. (+0.1 vs. -0.4 kg).Vildagliptin 50 mg bid added to insulin significantly reduced HbA1c in patients with T2DM inadequately controlled by insulin, with or without metformin. Vildagliptin was well tolerated, with a safety profile similar to placebo. These results were achieved without weight gain or an increase in hypoglycaemia incidence or severity in spite of improved

2013 EvidenceUpdates Controlled trial quality: uncertain

344. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin (Abstract)

Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin We compared metformin with insulin as treatment of gestational diabetes mellitus (GDM). Furthermore, we aimed to characterize metformin-treated patients needing additional insulin to achieve prespecified glucose targets.We conducted a single centre randomized controlled study with non-inferiority design comparing metformin and insulin in the treatment of 217 GDM (...) patients having birth weight as primary outcome variable.There were no significant differences in mean birth weight expressed in grams [+15 (90% confidence interval (CI): -121 to 89)] or SD units [+0.04 (90% CI: -0.27 to 0.18)] between the metformin and insulin groups. There were no significant differences in neonatal or maternal data between the groups. Only 23 (20.9%) of the 110 patients in the metformin group needed additional insulin. Compared with the patients on metformin only, those needing

2013 EvidenceUpdates Controlled trial quality: uncertain

345. Standing Orders for Insulin Administration in Hospitalized Patients with Type I or Type II Diabetes: Clinical Evidence

Standing Orders for Insulin Administration in Hospitalized Patients with Type I or Type II Diabetes: Clinical Evidence Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) for Insulin Administration in Hospitalized Patients with Type I or Type II Diabetes: Clinical Evidence DATE: 17 January 2013 RESEARCH QUESTION What is the clinical evidence regarding the effectiveness of standing insulin order protocols to guide subcutaneous insulin dosing and administration for the maintenance of glycemic control in hospitalized patients with type I or type II diabetes? KEY MESSAGE Two randomized controlled trials and six non-randomized studies were identified regarding the effectiveness

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

346. The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people Full Text available with Trip Pro

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (...) (IDeg), an ultra-long-acting basal insulin.This 26-week, open-label, treat-to-target trial enrolled adults (≥18 years) with type 2 diabetes who were either insulin naïve and receiving oral antidiabetic drugs (OADs) (HbA(1c) = 7-11%) or previously on basal insulin ± OAD(s) (HbA(1c) = 7-10%). Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8-40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg

2013 EvidenceUpdates Controlled trial quality: uncertain

347. Insulin detemir (Levemir®) 100 U/ml solution for injection

Insulin detemir (Levemir®) 100 U/ml solution for injection Insulin detemir (Levemir®) 100 U/ml solution for injection Insulin detemir (Levemir®) 100 U/ml solution for injection All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin detemir (Levemir®) 100 U/ml solution (...) for injection. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 3912. 2012 Authors' conclusions Insulin detemir (Levemir®) is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in children aged 2–5 years. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Child, Preschool; Diabetes Mellitus; Injections; Insulin, Long

2013 Health Technology Assessment (HTA) Database.

348. Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas Full Text available with Trip Pro

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).Patients were randomized (...) . Five (6%) patients in the EQW group and six (7%) patients in the detemir group experienced minor hypoglycemia; only one event occurred without concomitant sulfonylureas (detemir group).Treatment with EQW resulted in a significantly greater proportion of patients achieving target A1C and weight loss than treatment with detemir, with a low risk of hypoglycemia. These results suggest that EQW is a viable alternative to insulin detemir treatment in patients with type 2 diabetes with inadequate glycemic

2013 EvidenceUpdates Controlled trial quality: uncertain

349. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes

Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

350. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial Full Text available with Trip Pro

Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial This 52-week, randomized, multinational, open-label, parallel-group, non-inferiority trial investigated the efficacy and safety of basal-bolus treatment with insulin detemir vs. NPH (neutral protamine Hagedorn) insulin, in combination with insulin aspart, in subjects aged 2-16 years with Type 1 diabetes mellitus.Of the 347 randomized and exposed subjects, 177 received insulin detemir and 170 NPH insulin (...) , both administered once or twice daily in combination with mealtime insulin aspart. Glycaemic measurements and weight were followed over 52 weeks.After 52 weeks, insulin detemir was shown to be non-inferior to NPH insulin with regard to HbA(1c) [mean difference insulin detemir-NPH: 1.30 mmol/mol, 95% CI -1.32 to 3.92 (0.12%, 95% CI -0.12 to 0.36) in the full analysis set and 1.41 mmol/mol, 95% CI -1.26 to 4.08 (0.13%, 95% CI -0.12 to 0.37) in the per protocol analysis set]. Hypoglycaemic events per

2013 EvidenceUpdates Controlled trial quality: uncertain

351. Randomized Crossover Study to Examine the Necessity of an Injection-to-Meal Interval in Patients With Type 2 Diabetes Mellitus and Human Insulin Full Text available with Trip Pro

Randomized Crossover Study to Examine the Necessity of an Injection-to-Meal Interval in Patients With Type 2 Diabetes Mellitus and Human Insulin Patients with diabetes and insulin therapy with human insulin were usually instructed to use an interval of 20-30 min between the injection and meal. We examined the necessity of the injection-to-meal interval (IMI) in patients with type 2 diabetes mellitus (T2DM) and flexible insulin therapy with human insulin.In this randomized, open crossover trial (...) of the quality of life measure did not show differences between applying an IMI or not. Insulin therapy without IMI was preferred by 86.5% of patients (P < 0.001).An IMI for patients with T2DM and preprandial insulin therapy is not necessary.

2013 EvidenceUpdates Controlled trial quality: uncertain

352. Insulin: safe administration of

Insulin: safe administration of Insulin: from prescription to administration | Great Ormond Street Hospital Google Tag Manager Navigation Search Search You are here Insulin: from prescription to administration Insulin: from prescription to administration ) guidance “Safer Administration of Insulin” and supports best practice throughout the Trust. The aim of this document is to ensure that: The right patient receives the right type and dose of insulin, at the right time by the most appropriate (...) delivery device The most appropriate technique is used to inject insulin with the most commonly used insulin pens The most appropriate insulin syringe is used to prepare insulin for an insulin infusion Insulin therapy in diabetes Diabetes mellitus is a group of metabolic diseases characterised by chronic hyperglycaemia resulting from defects in insulin secretion, insulin action or both. Insulin is a polypeptide hormone produced by the beta cells in the pancreas that plays a key role in the regulation

2013 Publication 1593

353. Ryzodeg - insulin degludec / insulin aspart

Ryzodeg - insulin degludec / insulin aspart 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail nfo@ema.europa.eu Website www.ema.europa.eu 18 October 2012 EMA/700472/2012 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Ryzodeg International non-proprietary name: insulin degludec/insulin aspart Procedure No. EMEA/H/C/002499 Ryzodeg CHMP assessment (...) AUC area under the curve BB basal–bolus BID twice daily BMI body mass index C max maximum plasma concentration CGM continuous glucose monitoring CHMP Committee for Medicinal Products for Human Use CI confidence interval CSII continuous subcutaneous insulin infusion CV coefficient of variation CYP cytochrome P450 DPP-4 inhib dipeptidyl peptidase-4 inhibitor ECG electrocardiogram ELISA enzyme-linked immuno sorbent assay ESRD end-stage renal disease FAS full analysis set FF fixed flexible FPG fasting

2013 European Medicines Agency - EPARs

354. Tresiba - insulin degludec

Tresiba - insulin degludec 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu 20 September 2012 EMA/CHMP/557821/2012 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Tresiba International non-proprietary name: insulin degludec Procedure No. EMEA/H/C/002498 Tresiba CHMP assessment report Page 2/134 Table (...) AUC area under the curve BB basal–bolus BID twice daily BMI body mass index C max maximum plasma concentration CGM continuous glucose monitoring CHMP Committee for Medicinal Products for Human Use CI confidence interval CSII continuous subcutaneous insulin infusion CV coefficient of variation CYP cytochrome P450 DPP-4 inhib dipeptidyl peptidase-4 inhibitor ECG electrocardiogram ELISA enzyme-linked immuno sorbent assay ESRD end-stage renal disease FAS full analysis set FF fixed flexible FPG fasting

2013 European Medicines Agency - EPARs

355. Type 1 diabetes: insulin degludec

Type 1 diabetes: insulin degludec T T ype 1 diabetes: insulin degludec ype 1 diabetes: insulin degludec Evidence summary Published: 10 September 2013 nice.org.uk/guidance/esnm24 pathways This advice replaces ESNM5. K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary (...) The long-acting insulin analogue, insulin degludec, is available in 2 strengths: 100 units/ml and 200 units/ml. It is non-inferior to insulin glargine in terms of glycaemic control in type 1 diabetes, with statistically significantly lower rates of nocturnal hypoglycaemia. Although there is one published 104 week study reporting some safety data, there are no published studies comparing insulin degludec with NPH (isophane) insulin and none that measure patient-oriented efficacy outcomes. © NICE 2018

2013 National Institute for Health and Clinical Excellence - Advice

356. Type 2 diabetes: insulin degludec

Type 2 diabetes: insulin degludec T T ype 2 diabetes: insulin degludec ype 2 diabetes: insulin degludec Evidence summary Published: 10 September 2013 nice.org.uk/guidance/esnm25 pathways This advice replaces ESNM4. K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary (...) The long-acting insulin analogue, insulin degludec, is available in 2 strengths: 100 units/ml and 200 units/ml. It is non-inferior to insulin glargine in terms of glycaemic control in type 2 diabetes, with statistically significantly lower rates of some, but not all, measures of hypoglycaemia, particularly nocturnal hypoglycaemia. Although there are published studies with one year data, there are none comparing insulin degludec with NPH (isophane) insulin and none that measure patient-oriented efficacy

2013 National Institute for Health and Clinical Excellence - Advice

357. Cohort study: Appointment and medication non-adherence is associated with increased mortality in insulin-treated type 2 diabetes

Cohort study: Appointment and medication non-adherence is associated with increased mortality in insulin-treated type 2 diabetes Appointment and medication non-adherence is associated with increased mortality in insulin-treated type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Appointment and medication non-adherence is associated with increased mortality in insulin-treated type 2 diabetes Article Text Prognosis Cohort

2013 Evidence-Based Medicine

358. Effects of promoting longer-term and exclusive breastfeeding on adiposity and insulin-like growth factor-I at age 11.5 years: a randomized trial. Full Text available with Trip Pro

Effects of promoting longer-term and exclusive breastfeeding on adiposity and insulin-like growth factor-I at age 11.5 years: a randomized trial. Evidence that longer-term and exclusive breastfeeding reduces child obesity risk is based on observational studies that are prone to confounding.To investigate effects of an intervention to promote increased duration and exclusivity of breastfeeding on child adiposity and circulating insulin-like growth factor (IGF)-I, which regulates growth.Cluster

2013 JAMA Controlled trial quality: predicted high

359. Insulin degludec (Tresiba?): available in additional higher strength

Insulin degludec (Tresiba?): available in additional higher strength Insulin degludec (Tresiba▼): available in additional higher strength - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Insulin degludec (Tresiba▼): available in additional higher strength Care needed to minimise risk of error, including training for patients. Published 11 December 2014 From: Therapeutic area: Contents Article date: April 2013 Insulin degludec (Tresiba▼) has been developed as a once-daily basal (...) insulin for the treatment of glycaemia in adult patients with diabetes mellitus. While administration at the same time of day is preferable, Tresiba allows for some flexibility in the timing of insulin injections. A minimum of 8 hours between injections should always be ensured. Tresiba is available in pre-filled pen devices (called FlexTouch) in two strengths: 100 units/mL; and 200 units/mL. The 100 units/mL strength is also available in cartridge form (called Penfill, for use in specific insulin

2013 MHRA Drug Safety Update

360. Systematic review: Guidelines on glucose self-monitoring in non-insulin users are not evidence-based

Systematic review: Guidelines on glucose self-monitoring in non-insulin users are not evidence-based Guidelines on glucose self-monitoring in non-insulin users are not evidence-based | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Guidelines on glucose self-monitoring in non-insulin users are not evidence-based Article Text Practice guideline Systematic review Guidelines on glucose self-monitoring in non-insulin users are not evidence-based

2013 Evidence-Based Medicine